ACADIA Pharmaceuticals Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Catherine E. Owen Adams
- Full Time Employees
- 653
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12830 El Camino Real San Diego CA United States of America 92130
- IPO Date
- May 27, 2004
- CIK
- 0001070494
- Website
- acadia-pharm.com
- Similar Companies
- Business
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines targeting unmet medical needs in central nervous system disorders and rare diseases; its commercial portfolio features NUPLAZID (pimavanserin), the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), the first and only FDA-approved treatment for Rett syndrome in patients aged two years and older. The company advances a robust pipeline including mid- to late-stage candidates such as ACP-204 for Lewy body dementia psychosis and programs in Alzheimer's disease psychosis, alongside earlier-stage efforts addressing Prader-Willi syndrome negative symptoms, treatment-resistant depression (ACP-211), Huntington's disease and tardive dyskinesia (ACP-271), and essential tremor (ACP-711). ACADIA operates primarily in the United States and Canada, with international expansion underway including a Phase 3 trial of trofinetide for Rett syndrome in Japan; founded in 1993 as Receptor Technologies in Vermont and relocated to San Diego, California, in 1997, the company maintains headquarters at 12830 El Camino Real, Suite 400, San Diego, CA 92130. Recent developments include the initiation of a Phase 2 study for ACP-204 in Lewy body dementia psychosis and the Phase 3 Japan trial for trofinetide in 2025; appointment of Catherine Owen Adams as Chairperson of the Biotechnology Innovation Organization's Emerging Companies section and Executive Committee member; addition of Konstantina Katcheves as Senior Vice President and Chief Business and Strategy Officer to drive global partnerships and pipeline growth; extension of NUPLAZID patent protection to 2038; and an agreement in late 2024 to sell its rare pediatric disease priority review voucher for $150 million to fund commercial operations, R&D, and business development.
ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growth
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?
Mark Schneyer Sells 2,709 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock
Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report?
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Brokerages
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?